Elke Maas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Elke Maas has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- An Zwijsen
Department of Cardiovascular Sciences, KU Leuven
1 shared publication - Birgit Weynand
KU Leuven Department of Imaging and Pathology, Division of Translational Cell and Tissue Research, B-3000 Leuven, Belgium
1 shared publication - Hendrik Jan Thibaut
KU Leuven Department of Microbiology, Immunology & Transplantation, Rega Institute, Translational Platform Virus, Vaccine and Cancer Research (TPVC), Leuven, Belgium.
1 shared publication - Johan Neyts
KU Leuven Rega institute
1 shared publication - Joost Gribnau
Department of Developmental Biology, Erasmus University Medical Center, Rotterdam, The Netherlands
1 shared publication - Joran Degryse
KU Leuven Department of Microbiology, Immunology & Transplantation, Rega Institute, Division of Virology, Antiviral Drug & Vaccine Research, Laboratory of Molecular Vaccinology & Vaccine Discovery (MVVD), Leuven, Belgium
1 shared publication
Latest Publications
- Open Access
- 14 December 2024
- Published by MDPI AG in Microorganisms
- Vol. 12 (12) , 2591
Antigenic Imprinting Dominates Humoral Responses to New Variants of SARS-CoV-2 in a Hamster Model of COVID-19
The emergence of SARS-CoV-2 variants escaping immunity challenges the efficacy of current vaccines. Here, we investigated humoral recall responses and vaccine-mediated protection in Syrian hamsters immunized with the third-generation Comirnaty® Omicron XBB.1.5-adapted COVID-19 mRNA vaccine, followed by infection with either antigenically closely (EG.5.1) or distantly related (JN.1) Omicron subvariants. Vaccination with the YF17D vector encoding a modified Gamma spike (YF-S0*) served as a control for SARS-CoV-2 immunity restricted to pre-Omicron variants. Our results show that both Comirnaty® XBB.1.5 and YF-S0* induce robust, however, poorly cross-reactive, neutralizing antibody (nAb) responses. In either case, total antibody and nAb levels increased following infection. Intriguingly, the specificity of these boosted nAbs did not match the respective challenge virus, but was skewed towards the primary antigen used for immunization, suggesting a marked impact of antigenic imprinting, confirmed by antigenic cartography. Furthermore, limited cross-reactivity and rapid decline in nAbs induced by Comirnaty® XBB.1.5 with EG.5.1 and, more concerning, JN.1, raises doubts about sustained vaccine efficacy against recent circulating Omicron subvariants. In conclusion, we demonstrate that antigenic imprinting plays a dominant role in shaping humoral immunity against emerging SARS-CoV-2 variants. Future vaccine design may have to address two major issues: (i) overcoming original antigenic sin that limits the breadth of a protective response towards emerging variants, and (ii) achieving sustained immunity that lasts for at least one season.
- 14 December 2024
- Published by MDPI AG in Microorganisms
- Vol. 12 (12) , 2591
Open AccessAntigenic Imprinting Dominates Humoral Responses to New Variants of SARS-CoV-2 in a Hamster Model of COVID-19
The emergence of SARS-CoV-2 variants escaping immunity challenges the efficacy of current vaccines. Here, we investigated humoral recall responses and vaccine-mediated protection in Syrian hamsters immunized with the third-generation Comirnaty® Omicron XBB.1.5-adapted COVID-19 mRNA vaccine, followed by infection with either antigenically closely (EG.5.1) or distantly related (JN.1) Omicron subvariants. Vaccination with the YF17D vector encoding a modified Gamma spike (YF-S0*) served as a control for SARS-CoV-2 immunity restricted to pre-Omicron variants. Our results show that both Comirnaty® XBB.1.5 and YF-S0* induce robust, however, poorly cross-reactive, neutralizing antibody (nAb) responses. In either case, total antibody and nAb levels increased following infection. Intriguingly, the specificity of these boosted nAbs did not match the respective challenge virus, but was skewed towards the primary antigen used for immunization, suggesting a marked impact of antigenic imprinting, confirmed by antigenic cartography. Furthermore, limited cross-reactivity and rapid decline in nAbs induced by Comirnaty® XBB.1.5 with EG.5.1 and, more concerning, JN.1, raises doubts about sustained vaccine efficacy against recent circulating Omicron subvariants. In conclusion, we demonstrate that antigenic imprinting plays a dominant role in shaping humoral immunity against emerging SARS-CoV-2 variants. Future vaccine design may have to address two major issues: (i) overcoming original antigenic sin that limits the breadth of a protective response towards emerging variants, and (ii) achieving sustained immunity that lasts for at least one season.
- Open Access
RLIM enhances BMP signalling mediated fetal lung development in mice
RLIM, also called RNF12, is an X-linked E3 ubiquitin ligase. It is a pleotropic protein acting as a negative regulator of LIM-homeodomain transcription factors and of SMAD7, an antagonist of the BMP and TGFβ pathways. Mutations in RLIM are associated with variable congenital malformations in human. The molecular mechanism causing these malformations is still poorly understood. In this study, we used a conventional knockout (KO) mouse model to phenotypically characterize male mutants and to investigate the effect of Rlim mutation on BMP pathway signalling. Only 50% of KO male neonates survive and are significantly smaller. We show that Rlim deletion alters lung branching and maturation resulting in severe respiratory distress and neonatal death. Except for a single case of cardiac interventricular septal defect, no other malformations that mimic the human condition were observed. Western blot analysis shows that RLIM deficiency is associated with an increase of its target SMAD7 levels and a loss of SMAD1/5/9 activation. Interestingly, SMAD5 levels were diminished, suggesting another regulatory loop between RLIM and the BMP pathway. In conclusion, RLIM is important for lung development in mice and exerts this function in part through intracellular propagation of BMP signalling.
Open AccessRLIM enhances BMP signalling mediated fetal lung development in mice
RLIM, also called RNF12, is an X-linked E3 ubiquitin ligase. It is a pleotropic protein acting as a negative regulator of LIM-homeodomain transcription factors and of SMAD7, an antagonist of the BMP and TGFβ pathways. Mutations in RLIM are associated with variable congenital malformations in human. The molecular mechanism causing these malformations is still poorly understood. In this study, we used a conventional knockout (KO) mouse model to phenotypically characterize male mutants and to investigate the effect of Rlim mutation on BMP pathway signalling. Only 50% of KO male neonates survive and are significantly smaller. We show that Rlim deletion alters lung branching and maturation resulting in severe respiratory distress and neonatal death. Except for a single case of cardiac interventricular septal defect, no other malformations that mimic the human condition were observed. Western blot analysis shows that RLIM deficiency is associated with an increase of its target SMAD7 levels and a loss of SMAD1/5/9 activation. Interestingly, SMAD5 levels were diminished, suggesting another regulatory loop between RLIM and the BMP pathway. In conclusion, RLIM is important for lung development in mice and exerts this function in part through intracellular propagation of BMP signalling.